Table 2 Patient characteristics and PRS analysis

Primary tumor factor

  ≤ 65

1

 >65

1.187(0.936–1.506)

 Male

1

 Female

0.861(0.683–1.085)

 Never

1

1

 Ever

1.266(1.008–1.589)

1.847(0.541–6.313)

 IA

1

 IB

1.113(0.718–1.725)

 Lobectomy

1

 Sublobar resection

1.183(0.724–1.933)

 Adenocarcinoma (LUAD)

1

 Squamous carcinoma (LUSC)

1.344(1.016–1.778)

 Adenosquamous carcinoma (LASC)

1.319(0.823–2.113)

 Others

1.889(0.886–4.025)

 Adenocarcinoma (LUAD)

1

1

 Non-Adenocarcinoma (Non-LUAD)

1.375(1.074–1.762)

7.421(0.861–8.323)

 Low/immediate grade

1

1

 High grade

2.795(1.181–6.615)

3.740(1.405–9.953)

 Mutated

1

1

 Wild-type

2.140(1.307–3.503)

0.385(0.115–1.284)

 Absent

1

 Present

0.749(0.451–1.245)

 Absent

1

 Present

1.068(0.729–1.566)

 Local

1

 Distant

1.009(0.772–1.318)

 Intrathoracic

1

 Extrathoracic

0.756(0.543–1.053)

 Both

0.762(0.566–1.027)

 Single site

1

 Multiple site

1.004(0.728–1.148)

 Lung

1.198(0.837–1.715)

 Brain

1.442(1.013–2.051)

3.557(1.354–9.340)

 Bone

1.443(1.017–2.048)

2.397(1.026–5.601)

 Liver

1.139(0.685–1.893)

  Surgery

0.746(0.239–2.331)

  Chemotherapy

0.896(0.681–1.179)

  Radiation therapy

1.041(0.660–1.640)

  Targeted therapy

0.998(0.891–2.380)

 Chemotherapy+ radiation therapy/ targeted therapy

0.821(0.602–1.120)

 Surgery + Chemotherapy/radiation therapy/targeted therapy

0.758(0.530–0.984)

0.663(0.174–2.533)